In Vivo PICX CAR-T Therapy for R/R Multiple Myeloma

This study is an investigator-initiated, single-center, single-arm clinical study with a target population of patients with relapsed or refractory multiple myeloma. It is an early exploratory clinical study evaluating the safety, tolerability, and preliminary efficacy of PICX Injection, an in vivo prepared CAR-T cell therapy, in the treatment of relapsed or refractory multiple myeloma.

NCT Number	NCT07715630
Lead Sponsor	Chongqing Precision Biotech Co., Ltd
Conditions	Relapsed or Refractory Multiple Myeloma (RRMM)
Enrollment	15 participants
Start Date	2026-07-31
Primary Completion	2028-04-30 (estimated)
Study Completion	2028-07-31 (estimated)
Updated on ClinicalTrials.gov	2026-07-20